KMPH has been the subject of several other research reports. HC Wainwright reduced their price objective on shares of KemPharm from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, August 17th. Cantor Fitzgerald initiated coverage on shares of KemPharm in a research note on Thursday. They set an “overweight” rating and a $20.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of KemPharm in a research note on Thursday, September 15th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Canaccord Genuity Group reduced their price objective on shares of KemPharm from $20.00 to $19.00 in a research note on Thursday, November 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, KemPharm presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.
KemPharm Trading Up 4.3 %
KMPH opened at $4.64 on Friday. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.14. The firm has a 50-day moving average price of $5.71 and a 200-day moving average price of $5.27. KemPharm has a twelve month low of $4.00 and a twelve month high of $9.43.
Hedge Funds Weigh In On KemPharm
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.